The regulations in 21 CFR 312.42(c) require that when FDA concludes there may be grounds for imposing a clinical hold, FDA will Aattempt to discuss and satisfactorily resolve the matter with the sponsor before issuing the clinical hold order.@ FDA experience is that most potential holds, particularly those based on inadequate patient monitoring, can be resolved through such discussion.